Solid Biosciences to Detail Lead Gene Therapy Updates, Next-Gen Platforms at ASGCT Meeting
SLDB has more than doubled off its 52-week low of $2.41.
Summary
Solid Biosciences announced it will present its largest scientific program to date at the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), featuring 5 oral presentations and 11 posters. This follows the company's previous report of positive interim Phase 1/2 clinical data for its lead Duchenne muscular dystrophy candidate, SGT-003, in its last 10-K. The presentations will include an update on the INSPIRE DUCHENNE Phase 1/2 study for SGT-003, as well as efficacy and safety data for SGT-212 in Friedreich's Ataxia. Additionally, the company will showcase advancements in next-generation delivery technologies, capsid engineering, and scalable manufacturing. This significant presence at a major scientific conference provides important updates on key clinical programs and platform technologies, increasing the company's visibility and potentially serving as a catalyst for future stock movement as new data is revealed. Investors will be watching for the specific data and insights shared during these presentations at the ASGCT meeting (May 11-15, 2026).
At the time of this announcement, SLDB was trading at $7.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $693.7M. The 52-week trading range was $2.41 to $8.87. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.